OrphoMed: OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP101 for Treatment of IBSD
Interim Assessment Anticipated in Second Half of 2020 OrphoMed Inc. a clinicalstage biopharmaceutical company developing firstinclass dimer therapeutics today announced initiation of its PREVAIL trial a Phase 2 responseadaptive c...
Read full article »
OrphoMed is a biopharmaceutical company that develops dimer therapies for visceral hypersensitivity and hypermotility in gastrointestinal disorders.
Read more